Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Biomarker selection
3. Background
4. General considerations on biomarkers
5. Use of biomarkers in translational clinical R&D
6. General implications of molecular processes
7. Molecular processes in human
8. Molecular processes representation
9. Clinical phenotypes and disease terms
10. Disease terms and molecular processes
11. 1:1 relation
12. Phenotypes, molecular processes, biomarkers
13. Phenotypes, molecular processes, biomarkers (2)
14. Phenotypes, molecular processes, biomarkers (3)
15. 1:n relation
16. Example: diabetic nephropathy
17. Biomarkers for onset and progression of DN
18. Disease terms and underlying process view
19. Disease term process landscape (1)
20. Disease term process landscape (2)
21. Assumption
22. Options in biomarker discovery, applications (1)
23. Options in biomarker discovery, applications (2)
24. Implications and use
25. Biomarker panel discovery
26. Basis: annotated relations networks
27. Step 1: retrieve disease phenotype data
28. Step 2: populate an interaction network
29. Step 3: extract disease term-specific subgraph
30. Step 4: subgraph segmentation
31. Step 5: select for each process a marker
32. Result
33. Example: application of the steps
34. DN data retrieval and consolidation
35. DN subgraph construction
36. DN subgraph and molecular process model
37. Biomarker candidate panel selection
38. Recall: scope and purpose
39. Outlook: from marker panels to stratification
40. Summary and key issues
41. Acknowledgements
42. Thank you!

Topics Covered

• Biomarkers
• Molecular processes
• Disease terms
• Multimarker panels
• Cross-Omics
• Interaction networks
• Molecular disease models
• Biomarker selection
• Chronic disease
• Patient stratification

Links

Series:

• Clinical Proteomics

Categories:

• Biochemistry
• Cell Biology
• Clinical Practice
• Methods

Talk Citation

Mayer, B. (2013, November 5). A concept for multi-marker approaches in clinical proteomics [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 19, 2025, from https://doi.org/10.69645/RCUT3673.
Export Citation (RIS)

Publication History

• Published on November 5, 2013

Financial Disclosures

• Dr. Bernd Mayer, Grant/Research Support (Principal Investigator): European Union FP& project SysKid (Systems Biology towards novel chronic kidney disease diagnosis and treatment) ; Stock Shareholder (Self-managed): emergentec biodevelopment GmbH, Gersthofer Str. 29-31, 1180 Vienna, Austria.